Diffuse large B-cell lymphoma
LH Sehn, G Salles - New England Journal of Medicine, 2021 - Mass Medical Soc
Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Y Liu, SK Barta - American journal of hematology, 2019 - Wiley Online Library
Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …
Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
LH Sehn, AF Herrera, CR Flowers… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-
cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug …
cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug …
Genetic and functional drivers of diffuse large B cell lymphoma
A Reddy, J Zhang, NS Davis, AB Moffitt, CL Love… - Cell, 2017 - cell.com
Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …
Diffuse large B-cell lymphoma
S Li, KH Young, LJ Medeiros - Pathology, 2018 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …
worldwide, representing approximately 30–40% of all cases in different geographic regions …
Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma
MS Davids, AW Roberts, JF Seymour… - Journal of Clinical …, 2017 - ascopubs.org
Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-
Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to …
Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to …
Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma
D Ennishi, A Jiang, M Boyle, B Collinge… - Journal of Clinical …, 2019 - ascopubs.org
Purpose High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
(HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to …
(HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to …
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
SH Swerdlow, E Campo, SA Pileri… - Blood, The Journal …, 2016 - ashpublications.org
A revision of the nearly 8-year-old World Health Organization classification of the lymphoid
neoplasms and the accompanying monograph is being published. It reflects a consensus …
neoplasms and the accompanying monograph is being published. It reflects a consensus …
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase …
A Davies, TE Cummin, S Barrans, T Maishman… - The Lancet …, 2019 - thelancet.com
Background Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified
using gene-expression analysis to determine their cell of origin, corresponding to germinal …
using gene-expression analysis to determine their cell of origin, corresponding to germinal …
CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP
N Schmitz, S Zeynalova, M Nickelsen… - Journal of Clinical …, 2016 - ascopubs.org
Purpose To develop and validate a risk score for relapse in the CNS in patients with diffuse
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …